ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

LEO Pharma, 4SC Ink Dermatology Deal

by Rick Mullin
March 4, 2013 | APPEARED IN VOLUME 91, ISSUE 9

Leo Pharma, a Danish dermatology drug specialist, has signed a research and licensing agreement with Germany’s 4SC Discovery to research, develop, and commercialize an oral treatment for inflammatory skin disease. The partners say they are working on a compound in early-stage development that could significantly reduce symptoms of psoriasis. 4SC will receive $1.3 million in R&D financing and could get up to $125 million in milestone payments plus additional royalties.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment